Biological Drugs in the Treatment of Atopic Dermatitis: A Literature Review

Yıl 2024, , 36 - 51, 16.08.2024

Furkan Çalıcıoğlu , Neşecan Çalıcıoğlu , Atıl Avcı , Yılmaz Ulaş , Ragıp Ertaş

https://doi.org/10.55694/jamer.1410278

Öz

Atopic dermatitis is a chronic, pruritic, inflammatory skin condition that affects both children and adults, significantly
impacting patients’ quality of life due to itching, sleep disturbances caused by itching, social withdrawal, and
treatment expenses. The treatment of atopic dermatitis involves various approaches, including topical therapies,
phototherapy, systemic immunosuppressants, and biological agents. Biologics are particularly noteworthy for their
rapid onset of action and sustained ability to manage pruritus. Given their effectiveness in symptom control and
lower incidence of adverse effects compared to traditional immunosuppressive medications, biological drugs are
likely to see increased utilization in the future for treating atopic dermatitis. Ongoing research in this field is
expected to lead to the development and utilization of novel biologics. This study aims to provide a comprehensive
overview of phase studies and real-world data on the use of biological agents in atopic dermatitis treatment. The
objective is to analyze and discuss the drugs’ effects based on their mechanisms of action, clinical outcomes, side
effect profiles, treatment durability, and long-term safety considerations.

Anahtar Kelimeler

Atopic, antibodies, dermatitis, monoclonal

Atopik Dermatit Tedavisinde Biyolojik İlaçlar: Literatür Taraması

Öz

Atopik dermatit; kronik, kaşıntılı, inflamatuar bir deri hastalığıdır. Pediatrik dönemde ve erişkinlik döneminde
görülebilen atopik dermatit; kaşıntı, kaşıntıya bağlı uyku bozuklukları, sosyal geri çekilme ve tedavi maliyetleri
açısından hastanın yaşam kalitesini doğrudan etkilemektedir. Topikal tedaviler, fototerapi yöntemleri, sistemik
immünsupresif ilaçlar ve biyolojik ajanlar atopik dermatit tedavisinde kullanılmaktadır. Biyolojik ajanlar; hızlı
etki başlangıçları ve kaşıntının sürdürülebilir kontrolünde oldukça önemli bir rol üstlenmektedir. Semptomların
kontrolünde etkili ilaçlar olmaları ve konvansiyonel immünsupresif ilaçlara göre daha az yan etkiye sahip olmaları
sebebiyle biyolojik ajanlar atopik dermatit tedavisinde gelecekte daha sık kullanılabilir. Atopik dermatit tedavisi
ile ilgili araştırmalar sürdükçe yeni biyolojik ilaçlar üretilmeye ve kullanılmaya devam edecektir. Atopik dermatit
tedavisinde kullanılan biyolojik ajanların faz çalışmalarının sonuçlarını ve gerçek yaşam verilerini sentezleyerek
paylaşmak istiyoruz. Farklı mekanizmalar üzerinden ilaçların etkilerini, vaka sonuçlarını, karşılaşılan yan etkileri,
tedavi sürdürülebilirliğini ve uzun dönem risklerini bir bütün olarak ortaya koymayı ve tartışmayı amaçlıyoruz.

Anahtar Kelimeler

Atopik, antikorlar, dermatit, monoklonal

Etik Beyan

Derleme çalışmamız Dünya Helsinki Bildirgesine ve tıp etiği kurallarına uygun olarak hazırlanmıştır.

Kaynakça

• 1. Çalıcıoğlu F, Avcı A, Ertaş R, Ulaş Y. Atopik dermatit güncel patofizyolojisi. JAMER. 2024;9(1):1-7.
• 2. Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345-360.
• 3. Eichenfield LF, Stripling S, Fung S, Cha A, O’Brien A, Schachner LA. Recent developments and advances in atopic dermatitis: A focus on epidemiology, pathophysiology, and treatment in the pediatric setting. Paediatr Drugs. 2022;24(4):293-305.
• 4. Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338-351.
• 5. Paternoster L, Standl M, Waage J, Baurecht H, Hotze M, Strachan DP, et al. Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis. Nat Genet. 2015;47(12):1449-1456.
• 6. Garcovich S, Maurelli M, Gisondi P, Peris K, Yosipovitch G, Girolomoni G. Pruritus as a distinctive feature of type 2 inflammation. Vaccines (Basel). 2021;9(3):303.
• 7. Dubin C, Del Duca E, Guttman-Yassky E. The IL-4, IL-13 and IL-31 pathways in atopic dermatitis. Expert Rev Clin Immunol. 2021;17(8):835-852.
• 8. Boguniewicz M, Alexis AF, Beck LA, Block J, Eichenfield LF, Fonacier L et al. Expert perspectives on management of moderate- to-severe atopic dermatitis: A multidisciplinary consensus Addressing Current and Emerging Therapies. J Allergy Clin Immunol Pract. 2017 Nov-Dec;5(6):1519-1531.
• 9. Eichenfield LF, Hanifin JM, Luger TA, Stevens SR, Pride HB. Consensus conference on pediatric atopic dermatitis. J Am Acad Dermatol. 2003 Dec;49(6):1088-1095.
• 10. Ertam İ, Su Ö, Alper S, Sarıcaoğlu H, Karadağ A. S, Demirsoy E. O, ve ark. The Turkish guideline for the diagnosis and management of atopic dermatitis. Turkderm–Turk Arch Dermatol Venereol, 2018;52:6-23.
• 11. Ersser SJ, Cowdell F, Latter S, Gardiner E, Flohr C, Thompson AR, et al. Psycological and educational interventions for atopic eczema in children. Cochrane Database Syst Rev. 2014 Jan 7;2014(1):CD004054.
• 12. Staab D, Diepgen TL, Fartasch M, Kupfer J, Lob-Corzilius T, Ring J, et al. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. BMJ. 2006 Apr 22;332(7547):933-938.
• 13. Muller I, Stuart B, Sach T, Hooper J, Wilczynska S, Steele M, et al. Supporting self-care for eczema: protocol for two randomised controlled trials of ECO (Eczema Care Online) interventions for young people and parents/carers. BMJ Open. 2021 Feb 5;11(2): e045583.
• 14. Darsow U, Laifaoui J, Kerschenlohr K, Wollenberg A, Przybilla B, Wüthrich B et al. The prevalence of positive reactions in the atopy patch test with aeroallergens and food allergens in subjects with atopic eczema: a European multicenter study. Allergy. 2004 Dec;59(12):1318-1325.
• 15. Fu T, Keiser E, Linos E, Rotatori RM, Sainani K, Lingala B et al. Eczema and sensitization to common allergens in the United States: a multiethnic, population-based study. Pediatr Dermatol. 2014 Jan-Feb;31(1):21-26.
• 16. Garritsen FM, ter Haar NM, Spuls PI. House dust mite reduction in the management of atopic dermatitis. A critically appraised topic. Br J Dermatol. 2013 Apr;168(4):688-691.
• 17. Nankervis H, Pynn EV, Boyle RJ, Rushton L, Williams HC, Hewson DM et al. House dust mite reduction and avoidance measures for treating eczema. Cochrane Database Syst Rev. 2015 Jan 19;1(1):CD008426.
• 18. Ridd MJ, Santer M, MacNeill SJ, Sanderson E, Wells S, Webb D et al. Effectiveness and safety of lotion, cream, gel, and ointment emollients for childhood eczema: a pragmatic, randomised, phase 4, superiority trial. Lancet Child Adolesc Health. 2022 Aug;6(8):522-532.
• 19. Cardona ID, Kempe EE, Lary C, Ginder JH, Jain N. Frequent versus infrequent bathing in pediatric atopic dermatitis: A Randomized Clinical Trial. J Allergy Clin Immunol Pract. 2020 Mar;8(3):1014-1021.
• 20. Schram ME, Spuls PI, Leeflang MM, Lindeboom R, Bos JD, Schmitt J. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy. 2012 Jan;67(1):99-106.
• 21. Gaunt DM, Metcalfe C, Ridd M. The Patient-Oriented Eczema Measure in young children: responsiveness and minimal clinically important difference. Allergy. 2016 Nov;71(11):1620-1625
• 22. Bleehen SS, Chu AC, Hamann I, Holden C, Hunter JA, Marks R. Fluticasone propionate 0.05% cream in the treatment of atopic eczema: a multicentre study comparing once-daily treatment and once-daily vehicle cream application versus twice-daily treatment. Br J Dermatol. 1995 Oct;133(4):592-597.
• 23. Green C, Colquitt JL, Kirby J, Davidson P. Topical corticosteroids for atopic eczema: clinical and cost effectiveness of once-daily vs. more frequent use. Br J Dermatol. 2005 Jan;152(1):130-141.
• 24. Green C, Colquitt JL, Kirby J, Davidson P, Payne E. Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systematic review and economic evaluation. Health Technol Assess. 2004 Nov;8(47): 3,4, 1-120.
• 25. Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ. 2005 Mar 5;330(7490):516.
• 26. Rikkers SM, Holland GN, Drayton GE, Michel FK, Torres MF, Takahashi S. Topical tacrolimus treatment of atopic eyelid disease. Am J Ophthalmol. 2003 Mar;135(3):297-302.
• 27. Draelos ZD, Stein Gold LF, Murrell DF, Hughes MH, Zane LT. Post Hoc Analyses of the effect of crisaborole topical ointment, 2% on atopic dermatitis: Associated Pruritus from Phase 1 and 2 Clinical Studies. J Drugs Dermatol. 2016 Feb;15(2):172-176.
• 28. Stein Gold LF, Spelman L, Spellman MC, Hughes MH, Zane LT. A Phase 2, Randomized, controlled, dose-ranging study evaluating crisaborole topical ointment, 0.5% and 2% in adolescents with mild to moderate Atopic Dermatitis. J Drugs Dermatol. 2015 Dec;14(12):1394-1399.
• 29. Murrell DF, Gebauer K, Spelman L, Zane LT. Crisaborole TopicalOintment, 2% in Adults with atopic dermatitis: A phase IIa, vehicle-controlled, proof-of-concept Study. J Drugs Dermatol. 2015 Oct;14(10):1108-1112.
• 30. Zane LT, Kircik L, Call R, Tschen E, Draelos ZD, Chanda S et al. Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with atopic dermatitis: A phase 1b, open-label, maximal-use systemic exposure study. Pediatr Dermatol. 2016 Jul;33(4):380-387
• 31. Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Leung DYM et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021 Oct;85(4):863- 872.
• 32. Gong X, Chen X, Kuligowski ME, Liu X, Cimino E, McGee R et al. Pharmacokinetics of ruxolitinib in patients with atopic dermatitis treated with ruxolitinib cream: Data from Phase II and III Studies. Am J Clin Dermatol. 2021 Jul;22(4):555-566.
• 33. Nakagawa H, Nemoto O, Igarashi A, Saeki H, Kabashima K, Oda M et al. Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle- controlled study and a subsequent open-label, long-term study. J Am Acad Dermatol. 2021;85(4):854.
• 34. Nakagawa H, Nemoto O, Igarashi A, Saeki H, Kaino H, Nagata T. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. J Am Acad Dermatol. 2020;82(4):823.
• 35. Bissonnette R, Papp KA, Poulin Y, Gooderham M, Raman M, Mallbris L et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol. 2016 Nov;175(5):902-911.
• 36. Landis MN, Arya M, Smith S, Draelos Z, Usdan L, Tarabar S et al. Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study. Br J Dermatol. 2022 Dec;187(6):878-887.
• 37. Sidbury R, Davis DM, Cohen D, Cordoro KM, Berger TG, Bergman JN et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014 Aug;71(2):327-49.
• 38. Wollenberg A, Oranje A, Deleuran M, Simon D, Szalai Z, Kunz B et al. European Task Force on Atopic Dermatitis/EADV Eczema Task Force. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol. 2016 May;30(5):729-747.
• 39. Reynolds NJ, Franklin V, Gray JC, Diffey BL, Farr PM. Narrow- band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. Lancet. 2001 Jun 23;357(9273):2012-2016.
• 40. Proudfoot LE, Powell AM, Ayis S, Barbarot S, Baselga Torres E, Deleuran M et al. European Dermato-Epidemiology Network (EDEN). The European Treatment of severe Atopic eczema in children Taskforce (TREAT) survey. Br J Dermatol. 2013 Oct;169(4):901-909.
• 41. Totri CR, Eichenfield LF, Logan K, Proudfoot L, Schmitt J, Lara- Corrales I et al. Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: The PeDRA TREAT survey. J Am Acad Dermatol. 2017 Feb;76(2):281-285.
• 42. Taylor K, Swan DJ, Affleck A, Flohr C, Reynolds NJ; Translational Research Network in Dermatology and the U.K. Dermatology Clinical Trials Network. Treatment of moderate-to-severe atopic eczema in adults within the U.K.: results of a national survey of dermatologists. Br J Dermatol. 2017 Jun;176(6):1617-1623.
• 43. Drucker AM, Eyerich K, de Bruin-Weller MS, Thyssen JP, Spuls PI, Irvine AD et al.Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol. 2018 Mar;178(3):768-775.
• 44. Garrido Colmenero C, Blasco Morente G, Tercedor Sánchez J. Oral Cyclosporine Weekend Therapy: a new maintenance therapeutic option in patients with severe atopic dermatitis. Pediatr Dermatol. 2015 Jul-Aug;32(4):551-552.
• 45. Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2007 May;21(5):606-619.
• 46. Shea B, Swinden MV, Ghogomu ET, Ortiz Z, Katchamart W, Rader T et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. J Rheumatol. 2014 Jun;41(6):1049-1060.
• 47. Anderson K, Putterman E, Rogers RS, Patel D, Treat JR, Castelo- Soccio L. Treatment of severe pediatric atopic dermatitis with methotrexate: A retrospective review. Pediatr Dermatol. 2019 May;36(3):298-302.
• 48. Fuggle NR, Bragoli W, Mahto A, Glover M, Martinez AE, Kinsler VA. The adverse effect profile of oral azathioprine in pediatric atopic dermatitis, and recommendations for monitoring. J Am Acad Dermatol. 2015 Jan;72(1):108-114.
• 49. Flohr C, Irvine AD. Systemic therapies for severe atopic dermatitis in children and adults. J Allergy Clin Immunol. 2013 Sep;132(3):774-774.e6.
• 50. Grundmann-Kollmann M, Podda M, Ochsendorf F, Boehncke WH, Kaufmann R, Zollner TM. Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol. 2001 Jul;137(7):870-873.
• 51. Benez A, Fierlbeck G. Successful long-term treatment of severe atopic dermatitis with mycophenolate mofetil. Br J Dermatol. 2001 Mar;144(3):638-639.
• 52. Hansen ER, Buus S, Deleuran M, Andersen KE. Treatment of atopic dermatitis with mycophenolate mofetil. Br J Dermatol. 2000 Dec;143(6):1324-1326.
• 53. Grundmann-Kollmann M, Korting HC, Behrens S, Leiter U, Krähn G, Kaufmann R et al. Successful treatment of severe refractory atopic dermatitis with mycophenolate mofetil. Br J Dermatol. 1999 Jul;141(1):175-176.
• 54. Seegräber M, Srour J, Walter A, Knop M, Wollenberg A. Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol. 2018 May;11(5):467-474.
• 55. Guttman-Yassky E, Bissonnette R, Ungar B, Suárez-Fariñas M, Ardeleanu M, Esaki H et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019 Jan;143(1):155-172.
• 56. Kraft M, Worm M. Dupilumab in the treatment of moderate-to- severe atopic dermatitis. Expert Rev Clin Immunol. 2017 Apr;13 (4):301–310.
• 57. Regeneron and Sanofi Announce FDA approval of Dupixent® (dupilumab), The first targeted biological drug for adults moderate to severe atopic dermatitis [Internet]. Tarrytown, NY and Paris, FR; 2017
• 58. Silverberg JI, Yosipovitch G, Simpson EL, Kim BS, Wu JJ, Eckert L et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS. J Am Acad Dermatol. 2020 Jun;82(6):1328-1336.
• 59. Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Hultsch T, Davis JD et al. Dupilumab in adolescents with uncontrolled moderate- to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension. Br J Dermatol. 2020 Jan;182(1):85-96.
• 60. Licari A, Castagnoli R, Marseglia A, Olivero F, Votto M, Ciprandi G et al. Dupilumab to treat type 2 inflammatory diseases in children and adolescents. Paediatr Drugs. 2020 Jun;22(3):295-310.
• 61. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ et al. SOLO 1 and SOLO 2 Investigators. Two Phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016 Dec 15;375(24):2335-2348.
• 62. Deleuran M, Thaçi D, Beck LA, de Bruin-Weller M, Blauvelt A,Forman S et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J am acad dermatol. 2020 Feb;82(2):377-388.
• 63. Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D et al. Long term management of moderate-to- severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017 Jun 10;389(10086):2287-2303.
• 64. Ariëns LFM, van der Schaft J, Bakker DS, Balak D, Romeijn MLE, Kouwenhoven T et al. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry. Allergy. 2020 Jan;75(1):116-126.
• 65. Silverberg JI, Yosipovitch G, Simpson EL, Kim BS, Wu JJ, Eckert L et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS. J Am Acad Dermatol. 2020 Jun;82(6):1328-1336.
• 66. Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic Dermatitis: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2020 Jan 1;156(1):44-56.
• 67. Paller AS, Siegfried EC, Thaçi D, Wollenberg A, Cork MJ, Arkwright PD et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020 Nov;83(5):1282-1293. Epub 2020 Jun 20. Erratum in: J Am Acad Dermatol. 2021 Jan;84(1):230.
• 68. Blauvelt A, Guttman-Yassky E, Paller AS, Simpson EL, Cork MJ, Weisman J et al. Long-Term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE). Am J Clin Dermatol. 2022;23(3):365.
• 69. Fachler T, Shreberk-Hassidim R, Molho-Pessach V. Dupilumab- induced ocular surface disease: A systematic review. J Am Acad Dermatol. 2022 Feb;86(2):486-487.
• 70. Torres T, Paiva-Lopes MJ, Gonçalo M, Claro C, Oliveira M, Gomes J et al. Portuguese Group of Atopic Dermatitis. Dupilumab for atopic dermatitis: a real-world Portuguese multicenter retrospective study. J Dermatolog Treat. 2022 Aug;33(5):2554- 2559.
• 71. Neagu N, Dianzani C, Avallone G, Dell’Aquila C, Morariu SH, Zalaudek I et al. Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review. J Eur Acad Dermatol Venereol. 2022 Jun;36(6):820-835.
• 72. Brumfiel CM, Patel MH, Zirwas MJ. Development of psoriasis during treatment with dupilumab: A systematic review. J Am Acad Dermatol. 2022 Mar;86(3):708-709.
• 73. Jay R, Rodger J, Zirwas M. Review of dupilumab-associated inflammatory arthritis: An approach to clinical analysis and management. JAAD Case Rep. 2022 Jan 6;21: 14-18.
• 74. Willsmore ZN, Woolf RT, Hughes C, Menon B, Kirkham B, Smith CH et al. Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series. Br J Dermatol. 2019 Nov;181(5):1068-1070.
• 75. Bridgewood C, Newton D, Bragazzi N, Wittmann M, McGonagle D. Unexpected connections of the IL-23/IL-17 and IL-4/IL-13 cytokine axes in inflammatory arthritis and enthesitis. Semin Immunol. 2021 Dec; 58:101520.
• 76. Jo CE, Finstad A, Georgakopoulos JR, Piguet V, Yeung J, Drucker AM. Facial and neck erythema associated with dupilumab treatment: A systematic review. J Am Acad Dermatol. 2021 May;84(5):1339-1347.
• 77. Soria A, Du-Thanh A, Seneschal J, Jachiet M, Staumont-Sallé D, Barbarot S; GREAT research group. Development or exacerbation of head and neck dermatitis in patients treated for atopic dermatitis With Dupilumab. JAMA Dermatol. 2019 Nov 1;155(11):1312-1315.
• 78. Waldman RA, DeWane ME, Sloan B, Grant-Kels JM. Characterizing dupilumab facial redness: A multi-institution retrospective medical record review. J Am Acad Dermatol. 2020 Jan;82(1):230-232.
• 79. Bax CE, Khurana MC, Treat JR, Castelo-Soccio L, Rubin AI, McMahon PJ. New-onset head and neck dermatitis in adolescent patients after dupilumab therapy for atopic dermatitis. Pediatr Dermatol. 2021 Mar;38(2):390-394.
• 80. Muzumdar S, Zubkov M, Waldman R, DeWane ME, Wu R, Grant- Kels JM. Characterizing dupilumab facial redness in children and adolescents: A single-institution retrospective chart review. J Am Acad Dermatol. 2020 Nov;83(5):1520-1521.
• 81. Hamp A, Hanson J, Schwartz RA, Lambert WC, Alhatem A. Dupilumab-associated mycosis fungoides: a cross-sectional study. Arch Dermatol Res. 2023 Nov;315(9):2561-2569.
• 82. Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP et al. ECZTRA 1 and ECZTRA 2 study investigators. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021 Mar;184(3):437-449.
• 83. Silverberg JI, Toth D, Bieber T, Alexis AF, Elewski BE, Pink AE et al. ECZTRA 3 study investigators. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021 Mar;184(3):450-463.
• 84. Paller AS, Flohr C, Cork M, Bewley A, Blauvelt A, Hong HC et al. Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial JAMA Dermatol. 2023;159(6):596.
• 85. Gutermuth J, Pink AE, Worm M, Soldbro L, Bjerregård Øland C, Weidinger S. Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7). Br J Dermatol. 2022 Mar;186(3):440-452.
• 86. Newsom M, Bashyam AM, Balogh EA, Feldman SR, Strowd LC. New and emerging systemic treatments for atopic dermatitis. Drugs. 2020 Jul;80(11):1041-1052.
• 87. Guttman-Yassky E, Blauvelt A, Eichenfield LF, Paller AS, Armstrong AW, Drew J et al. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial. JAMA Dermatol. 2020 Apr 1;156(4):411-420.
• 88. Simpson EL, Gooderham M, Wollenberg A, Weidinger S, Armstrong A, Soung J et al. Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: A Randomized Clinical Trial (ADhere). JAMA Dermatol. 2023 Feb 1;159(2):182- 191.
• 89. Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A et al. ADvocate1 and ADvocate2 Investigators. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023 Mar 23;388(12):1080-1091.
• 90. Blauvelt A, Thyssen JP, Guttman-Yassky E, Bieber T, Serra- Baldrich E, Simpson E et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol. 2023 May 24;188(6):740-748.
• 91. Guttman-Yassky E, Brunner PM, Neumann AU, Khattri S, Pavel AB, Malik K. et al. Efficacy and safety of fezakinumab (an IL- 22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase IIa trial. J Am Acad Dermatol. 2018 May;78(5):872-881.e6.
• 92. Silverberg JI, Pinter A, Pulka G, Poulin Y, Bouaziz JD, Wollenberg A et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020 Jan;145(1):173-182.
• 93. Ruzicka T, Hanifin JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A et al. XCIMA study group. Anti-Interleukin-31 receptor a antibody for atopic dermatitis. N Engl J Med. 2017 Mar 2;376(9):826-835.
• 94. Kabashima K, Matsumura T, Komazaki H, Kawashima M; Nemolizumab-JP01 Study Group. Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus. N Engl J Med. 2020 Jul 9;383(2):141-150.
• 95. ClinicalTrials.gov [Internet] Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab. Available from: https://www.clinicaltrials.gov/ study/NCT05694884?cond=eblasakimab&rank=1
• 96. Guttman-Yassky E, Pavel AB, Zhou L, Estrada YD, Zhang N, Xu H et al. GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. J Allergy Clin Immunol. 2019 Aug;144(2):482-493.e7.
• 97. Guttman-Yassky E. Efficacy and Safety Results of KHK4083/ AMG 451 (anti-OX40 mAb) in Subjects with Moderate to Severe Atopic Dermatitis: A Phase 2, Multicentre, Randomized, Double- Blind, Parallel-Group, Placebo-Controlled Study. Proceedings of the 30th European Academy of Dermatology and Venereology (EADV) Congress, Vienna, Austria, October 2021.
• 98. Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R et al. Baricitinib in patients with moderate- to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020 Aug;183(2):242-255.
• 99. Reich K, Simpson E, Wollenberg A, Bissonnette R, Abe M, Cardillo T et al. Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3. Br J Dermatol. 2023 Feb 10;188(2):208-217.
• 100. Bieber T, Reich K, Paul C, Tsunemi Y, Augustin M, Lacour JP et al. BREEZE-AD4 study group. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE- AD4). Br J Dermatol. 2022 Sep;187(3):338-352.
• 101. Torrelo A, Rewerska B, Galimberti M, Paller A, Yang CY, Prakash A et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to- severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double- blind, placebo-controlled study (BREEZE-AD PEDS). Br J Dermatol. 2023;189(1):23.
• 102. Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020 Jul 25;396(10246):255-266.
• 103. Bieber T, Simpson EL, Silverberg JI, Thaçi D, Paul C, Pink AE et al. JADE COMPARE Investigators. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021 Mar 25;384(12):1101-1112.
• 104. Reich K, Thyssen JP, Blauvelt A, Eyerich K, Soong W, Rice ZP et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet. 2022 Jul 23;400(10348):273-282.
• 105. Eichenfield LF, Flohr C, Sidbury R, Siegfried E, Szalai Z, Galus R et al. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: The JADE TEEN Randomized Clinical Trial. JAMA Dermatol. 2021 Oct 1;157(10):1165-1173.
• 106. Thyssen JP, Yosipovitch G, Paul C, Kwatra SG, Chu CY, DiBonaventura M et al. Patient-reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2022 Mar;36(3):434-443.
• 107. Shi VY, Bhutani T, Fonacier L, Deleuran M, Shumack S, Valdez H et al. Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND). J Am Acad Dermatol. 2022 Aug;87(2):351-358.
• 108. Blauvelt A, Silverberg JI, Lynde CW, Bieber T, Eisman S, Zdybski J et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to severe atopic dermatitis: Results from the JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol. 2022 Jan;86(1):104-112.
• 109. Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021 Jun 5;397(10290):2151-2168.
• 110. Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021 Jun 5;397(10290):2169-2181.
• 111. Paller AS, Ladizinski B, Mendes-Bastos P, Siegfried E, Soong W, Prajapati VH et al. Efficacy and safety of upadacitinib treatment in adolescents with moderate-to-severe atopic dermatitis: Analysis of the measure up 1, measure Up 2, and AD up randomized clinical trials. JAMA Dermatol. 2023 May 1;159(5):526-535.
• 112. Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin- Weller M, Barbarot S et al. Efficacy and Safety of Upadacitinib vs Dupilumab in adults with moderate-to-severe atopic dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2021 Sep 1;157(9):1047-1055.
• 113. Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A et al. Safety profile of upadacitinib over 15 000 patient- years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023 Feb;9(1): e002735.
• 114. Grieco T, Caviglia M, Cusano G, Sernicola A, Chello C, Del Duca E et al. Atopic dermatitis and ulcerative colitis successfully treated with upadacitinib. Medicina (Kaunas). 2023 Mar 10;59(3):542. 115. Katoh N, Ohya Y, Murota H, Ikeda M, Hu X, Ikeda K et al. Safety and efficacy of upadacitinib for atopic dermatitis in Japan: 2-year interim results from the phase 3 rising up study. Dermatol Ther (Heidelb). 2023 Jan;13(1):221-234.
• 116. Sawangjit R, Dilokthornsakul P, Lloyd-Lavery A, Lai NM, Dellavalle R, Chaiyakunapruk N. Systemic treatments for eczema: a network meta-analysis. Cochrane Database Syst Rev. 2020 Sep 14;9(9):CD013206.
• 117. Chen YT, Chiu HY. Short-term risks of major adverse cardiovascular events associated with Janus kinase inhibitors in patients with atopic dermatitis: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2023 Apr 5.
• 118. Wan H, Jia H, Xia T, Zhang D. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis. Dermatol Ther. 2022 Sep;35(9): e15636.
• 119. Drucker AM, Morra DE, Prieto-Merino D, Ellis AG, Yiu ZZN, Rochwerg B et al. Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis. JAMA dermatol. 2022 May 1;158(5):523-532.
• 120 Escolằ H, Figueras-Nart I, Bonfill-Orti M, Coll Puigserver N, Martin-Santiago A, Rodriguez Serna M et al. Dupilumab for atopic dermatitis during pregnancy and breastfeeding: Clinical experience in 13 patients. J Eur Acad Dermatol Venereol. 2023;37(9):e1156-e1160.
• 121. Boesjes CM, van der Gang LF, Bakker DS, Ten Cate TA, Spekhorst LS, de Graaf M et al. Dupilumab-Associated lymphoid reactions in patients with atopic dermatitis. JAMA Dermatol. 2023;159(11):1240-1247.
• 122. Blauvelt A, Ladizinski B, Prajapati VH, Laquer V, Fischer A, Eisman S et al. Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to- severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up).J Am Acad Dermatol. 2023;89(3):478-485.
• 123. Guttman-Yassky E, Silverberg JI, Nemoto O, Forman SB, Wilke A, Prescilla R et al. Baricitinib in adult patients with moderate- to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol. 2019;80(4):913-921.e9.
• 124. Rosmarin D, Casillas M, Chen S, Dawson Z, Pierce E, Zhang H et al. Onset of symptom relief reported in daily diaries of patients with atopic dermatitis treated with Baricitinib in a United States Clinical Trial (BREEZE-AD5). J Cutan Med Surg. 2022;26(3):262- 266.
• 125. ClinicalTrials.gov [Internet] A study of Baricitinib (LY3009104) in participants with moderate to severe atopic dermatitis (BREEZE-AD6). Available from https://clinicaltrials.gov/study/ NCT03559270.